[Multiple myeloma : What has been confirmed in therapy?]

about

[Multiple myeloma : What has been confirmed in therapy?]

Item

http://www.wikidata.org/entity/Q52817414

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

[Multiple myeloma : What has been confirmed in therapy?]

@en

[Multiple myeloma : What has been confirmed in therapy?]

@nl

type

Item

label

[Multiple myeloma : What has been confirmed in therapy?]

@en

[Multiple myeloma : What has been confirmed in therapy?]

@nl

prefLabel

[Multiple myeloma : What has been confirmed in therapy?]

@en

[Multiple myeloma : What has been confirmed in therapy?]

@nl

P1476

[Multiple myeloma : What has been confirmed in therapy?]

@en

P2093

H Goldschmidt

http://www.w3.org/2001/XMLSchema#string

M-A Baertsch

http://www.w3.org/2001/XMLSchema#string

P2860

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-l

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

European Myeloma Network guidelines for the management of multiple myeloma-related complications.

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.

P304

1250-1257

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00108-017-0337-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29098319

http://www.w3.org/2001/XMLSchema#string